Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pharmacokinetics of 3 Doses of AZD5718 in Healthy Volunteers
NCT04087187Phase 1Completed
- Sponsor
- AstraZeneca
- Start
- Sep 2019
- Primary completion
- Oct 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of atuliflapon in coronary artery disease (CAD) (6 arms), sponsored by AstraZeneca. Primary endpoints: Area under plasma concentration time curve from zero to infinity, Area under the plasma concentration curve from time zero to time of last quantifiable concentration and 5 more. Started Sep 2019; status: completed.
02
Drugs
atuliflapon
03
Conditions
coronary artery disease (CAD)
Beyond the preview
Go deeper on NCT04087187.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04087187.